• FirefoxInstall the new Firefox »
  •  Dow Up0.61% Nasdaq Up0.60%

    Supernus Pharmaceuticals, Inc. (SUPN)

    -NasdaqGM
    9.24 Up 0.25(2.78%) 11:02AM EST - Nasdaq Real Time Price
    Add to Portfolio
    Income StatementGet Income Statement for:
    View: Annual Data | Quarterly DataAll numbers in thousands
    Period EndingSep 30, 2014Jun 30, 2014Mar 31, 2014Dec 31, 2013
    Total Revenue 52,488   29,675   9,081   10,335  
    Cost of Revenue1,321  1,661  494  1,067  
    Gross Profit 51,167   28,014   8,587   9,268  
    Operating Expenses
    Research Development4,657  4,677  4,482  5,401  
    Selling General and Administrative17,343  19,582  17,527  15,224  
    Non Recurring -   -   -   -  
    Others -   -   -   -  
    Total Operating Expenses -   -   -   -  
    Operating Income or Loss 29,167   3,755   (13,422) (11,357)
    Income from Continuing Operations
    Total Other Income/Expenses Net(20)724  (914)(8,942)
    Earnings Before Interest And Taxes30,007  4,518  (12,643)(21,461)
    Interest Expense1,289  1,278  1,207  2,107  
    Income Before Tax28,718  3,240  (13,850)(23,568)
    Income Tax Expense -   -   -   -  
    Minority Interest -   -   -   -  
    Net Income From Continuing Ops27,858  3,201  (15,543)(22,406)
    Non-recurring Events
    Discontinued Operations -   -   -   -  
    Extraordinary Items -   -   -   -  
    Effect Of Accounting Changes -   -   -   -  
    Other Items -   -   -   -  
    Net Income 27,858   3,201   (15,543) (22,406)
    Preferred Stock And Other Adjustments -   -   -   -  
    Net Income Applicable To Common Shares 27,858   3,201   (15,543) (22,406)

    Sign Up for a Free Trial to EDGAR Online Premium!
    Get the critical business and financial information you need for more than 15,000 U.S. public companies.
    Sign Up Now - Learn More

    Currency in USD.